TITANIUM PROFESSIONALS

A research team led by Prof. LIU Qingsong and Prof. LIU Jing from the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has recently developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant mutant form, offering a promising strategy for treating hematological malignancies.

A new study by University of Bath scientists has highlighted two new potential families of drug molecules that could open the door to new treatments for tuberculosis.

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is the second largest infectious killer globally after COVID-19 and causes 1.3 million deaths annually.

A new study led by researchers at Lund University in Sweden, reveals that melanoma, the deadliest form of skin cancer, can in some cases be driven by mitochondrial processes, which can be effectively targeted using existing drugs. In preclinical laboratory experiments with melanoma cell cultures, researchers successfully eliminated cancer cells by using antibiotics and inhibitors of mitochondrial energy production, highlighting a potential therapeutic breakthrough.

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials. The research was the first to comprehensively quantify these barriers for an international platform trial and emphasizes the need for urgent improvements, particularly in preparing for future public health crises.

Researchers working on an incurable blood cancer can now use a new lab model which could make testing potential new treatments and diagnostics easier and quicker, new research has found.

In a paper published in Nature Communications a team of researchers led from the University of Birmingham have studied blood cells from patients with a blood cancer called myelodysplastic syndrome disease (MDS).

Chronic inflammation occurs when the immune system is stuck in attack-mode, sending cell after cell to defend and repair the body for months or even years. Diseases associated with chronic inflammation, like arthritis or cancer or autoimmune disorders, weigh heavily on human health - and experts anticipate their incidence is on the rise. A new study by investigators from Mass General Brigham identified a protein called WSTF that could be targeted to block chronic inflammation.

Gene therapy can improve hearing in children and adults with congenital deafness or severe hearing impairment, a new study involving researchers at Karolinska Institutet reports. Hearing improved in all ten patients, and the treatment was well-tolerated. The study was conducted in collaboration with hospitals and universities in China and is published in the journal Nature Medicine.

A new study published in Nutrients offers new insight into omega-6 and whether it is truly the proinflammatory fatty acid many claim it to be.

There is currently a heightened interest in the health effects of seed oils, many of which are rich in linoleic acid (LA), an essential omega-6 fatty acid.

A new study published in The Lancet has raised urgent concerns about the global health consequences of recent cuts to U.S. foreign aid. The study, coordinated by researchers from the Barcelona Institute for Global Health (ISGlobal), together with the Institute of Collective Health of the Federal University of Bahia (ISC-UFBA), the University of California Los Angeles (UCLA), and the Manhiça Centre for Health Research (CISM), among others, estimates that 91 million deaths were prevented between 2001 and 2021 in low- and middle-income countries (LMICs)

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

Type 2 diabetes (T2D), a condition in which the body can't use insulin to clear sugar from the bloodstream, affects 1 in 10 Americans. It comes with grave health risks, including cardiovascular and kidney disease.

Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.

Lower blood sugar and increased fat burning - without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss. In animal tests, the compound prevented fat accumulation in response to a high-fat diet, treated existing obesity, and reversed associated metabolic disorders, including insulin resistance.

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

The results were published in the journal NEJM Evidence.

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98.

In a study published in the journal Nature Machine Intelligence, Sheffield computer scientists in collaboration with AstraZeneca and the University of Southampton have developed a new machine learning framework that has shown the potential to be more accurate at inverse protein folding than existing state-of-the-art methods.

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.

Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a protective function against these prevalent diseases, as it burns calories and can produce body heat from fat. But as the body ages, the activity of brown adipose tissue decreases. This inactivation of brown adipose tissue - also typical of obese people - remains poorly studied in the scientific literature.

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer. By combining two antioxidant enzyme inhibitors, they have converted cancer cells in mice into healthy nerve cells. The study is published in the journal Proceedings of the National Academy of Sciences (PNAS).

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment of cancer and in the prescription of medicines. As recently published in Nature Communications, Jinze Liu, Ph.D., and Kevin Byrd, D.D.S., Ph.D., created Threshold-based Assignment of Cell Types from Multiplexed Imaging Data (TACIT), which assigns cell identities based on cell-marker expression profiles.